Compare Fiverr International Ltd (FVRR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Medpace Holdings Inc — how do they compare? Fiverr International Ltd trades at $8.72 (market cap $310.61M), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 54.2× Fiverr International Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Medpace Holdings Inc for 14 Days on average.
| FVRR | MEDP | |
|---|---|---|
Market Cap | $310.61M | $16.82B |
Volume | 381,459 | 223,093 |
Sector | Media | Health |
52-Week High | $23.60 | $630.19 |
52-Week Low | $8.47 | $393.42 |
Typical Hold Time | 62 Days | 14 Days |
Enterprise Value | $63.00M | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.64, up 1.65% on the day, amid a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. Revenue for 2025 reached $430.91M with a net income margin of 7.18%, though 2026 revenue is projected to dip to $418M. Valuation ratios appear attractive with a P/E of 10.67 and P/S of 0.76, but the stock faces headwinds from AI disruption compressing demand for freelance services, as highlighted in recent news.
The stock's outlook is cautious, with analyst consensus leaning Hold (76.47%) and a price target of $10.50 offering potential upside. Key risks include AI-driven market shifts and competitive pressures, while the current low valuation may appeal to value investors if the company navigates transitional challenges successfully.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
